SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Mirum Reports Positive Atebrioz Study Results in Pediatric Patients

Mirum Pharmaceuticals announced positive results from Cohort 2 of the pivotal PROGRESS study of atebrioz (zilurgisertib) in pediatric patients aged 6 to under 12 with fibrodysplasia ossificans progressiva.

MIRM

Related stories